Zaloguj się

Gotowe bibliografie tematyczne / Drugs design / Artykuły w czasopismach

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Drugs design.

Artykuły w czasopismach na temat „Drugs design”

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 30 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Drugs design”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Bugg, Charles E., William M. Carson i John A. Montgomery. "Drugs by Design". Scientific American 269, nr 6 (grudzień 1993): 92–98. http://dx.doi.org/10.1038/scientificamerican1293-92.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

BORMAN, STU. "DRUGS BY DESIGN". Chemical & Engineering News Archive 83, nr 48 (28.11.2005): 28–30. http://dx.doi.org/10.1021/cen-v083n048.p028.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Krasnopolsky, Yu М. ""QUALITY BY DESIGN" IN LIPOSOMAL DRUGS CREATION". Biotechnologia Acta 13, nr 6 (grudzień 2020): 5–12. http://dx.doi.org/10.15407/biotech13.06.005.

Pełny tekst źródła

Streszczenie:

Nanobiotechnological preparations creation is one of the promising areas of modern pharmacy, since it allows creating products of a qualitatively new level. The procedure development, based on an understanding of the product characteristics and the technological process, confirmed by reliable scientific data. The article is devoted to the pharmaceutical development of liposomal drugs. On the basis of our own experience in the development of liposomal medicinal forms, as well as on the basis of literature data, the main components in their composition were detected and these components impact on the quality indicators of liposomes were studied. Individual lipids function in nanoparticle membrane and their interaction, which determines the stability both in the technological process and upon storage of the product, were considered. The advantages and disadvantages of cholesterol incorporation into liposomes with hydrophilic and hydrophobic active pharmaceutical ingredients were described. Cryoprotectors and buffer systems role in ensuring nanopreparation stability is discussed.

Style APA, Harvard, Vancouver, ISO itp.

4

Snyder, Solomon H. "Pharmacology: Virtuoso design of drugs". Nature 323, nr 6086 (wrzesień 1986): 292–93. http://dx.doi.org/10.1038/323292a0.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Williams, Bryan R. G. "Design of anti-AIDS drugs". Virus Research 19, nr 1 (marzec 1991): 130. http://dx.doi.org/10.1016/0168-1702(91)90102-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

YOKOYAMA, MASAYUKI. "Molecular design of missile drugs." Kagaku To Seibutsu 26, nr 3 (1988): 199–202. http://dx.doi.org/10.1271/kagakutoseibutsu1962.26.199.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Ferriz, J. M., i J. Vinsova. "Prodrug Design of Phenolic Drugs". Current Pharmaceutical Design 16, nr 18 (1.06.2010): 2033–52. http://dx.doi.org/10.2174/138161210791293042.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Isnenia, Isnenia. "Penggunaan Non-Steroid Antiinflamatory Drug dan Potensi Interaksi Obatnya Pada Pasien Muskuloskeletal". Pharmaceutical Journal of Indonesia 6, nr 1 (1.12.2020): 47–55. http://dx.doi.org/10.21776/ub.pji.2020.006.01.8.

Pełny tekst źródła

Streszczenie:

The main therapy on musculoskeletal patients is the use of non-steroidal anti-inflammatory drugs (NSAIDs) either as monotherapy or in combination with drugs of the same class or pain relievers from other groups. The use of more than one drugs have potentially caused drug-drug interactions that can affect to patient. This study was aimed to describe the patient's sociodemographic (sex, ages) and clinical (numbers of drugs, type of drugs and diagnose) characteristics, as well as to find the correlation between potential drug interactions with these variables. This research was a quantitative study with a cross sectional design. Data were taken from 100 medical records of patients who had diagnosed with top five musculoskeletal diseases. Data were analyzed descriptively for sex, ages, number of drugs, type of drugs, and potential drug interactions. Bivariate correlation with chi-square were conducted to find statistically significancy potential drug interactions with each variable consist of sex, ages, type of drugs and it’s diagnose. The result shows that the musculoskeletal patients were 44% male, 56% female. Most musculoskeletal patients were aged 18-65 years (78%). Patients who received drugs <5 were 68% and ≥ 5 were 32%. 54% of patients were taking the diclofenac and only 5% of patients were taking the two NSAIDs combination, diclofenac and ibuprofen. There was no significant correlation (p > 0,05) between potential drug interactions with age, sex, type of NSAID, and type of musculosceletal diseases.

Style APA, Harvard, Vancouver, ISO itp.

9

Carlson, Robert. "Supercomputers help design drugs super fast". Inpharma Weekly &NA;, nr 1155 (wrzesień 1998): 9–10. http://dx.doi.org/10.2165/00128413-199811550-00019.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Korcsmáros, Tamás, Máté S. Szalay, Csaba Böde, István A. Kovács i Péter Csermely. "How to design multi-target drugs". Expert Opinion on Drug Discovery 2, nr 6 (czerwiec 2007): 799–808. http://dx.doi.org/10.1517/17460441.2.6.799.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Immadisetty, Kalyan, Laura M. Geffert, Christopher K. Surratt i Jeffry D. Madura. "New design strategies for antidepressant drugs". Expert Opinion on Drug Discovery 8, nr 11 (31.08.2013): 1399–414. http://dx.doi.org/10.1517/17460441.2013.830102.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

Malik, Ravinder, i Ipsita Roy. "Design and development of antisense drugs". Expert Opinion on Drug Discovery 3, nr 10 (28.09.2008): 1189–207. http://dx.doi.org/10.1517/17460441.3.10.1189.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Lipkin, R. "New 'Design Rules' Yield Novel Drugs". Science News 147, nr 24 (17.06.1995): 374. http://dx.doi.org/10.2307/3978896.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Nussinov, Ruth, i Chung-Jung Tsai. "The Design of Covalent Allosteric Drugs". Annual Review of Pharmacology and Toxicology 55, nr 1 (6.01.2015): 249–67. http://dx.doi.org/10.1146/annurev-pharmtox-010814-124401.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Navia, M. A. "Rational design of new immunosuppressive drugs". Transplantation Proceedings 31, nr 1-2 (luty 1999): 1097–98. http://dx.doi.org/10.1016/s0041-1345(98)01917-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

HOPKINS, A., J. MASON i J. OVERINGTON. "Can we rationally design promiscuous drugs?" Current Opinion in Structural Biology 16, nr 1 (luty 2006): 127–36. http://dx.doi.org/10.1016/j.sbi.2006.01.013.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Shugar, David. "Design of enzyme inhibitors as drugs". FEBS Letters 258, nr 2 (4.12.1989): 355. http://dx.doi.org/10.1016/0014-5793(89)81692-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Tomlinson, E. "Design of site-specific protein drugs". Science of The Total Environment 109-110 (grudzień 1991): 9–16. http://dx.doi.org/10.1016/0048-9697(91)90166-c.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Whiteley, John M. "Design of enzyme inhibitors as drugs". Trends in Biochemical Sciences 14, nr 10 (październik 1989): 427–28. http://dx.doi.org/10.1016/0968-0004(89)90305-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Taylor, Buck. "Giveaway Drugs: Good Intentions, Bad Design". Health Affairs 23, nr 1 (styczeń 2004): 213–17. http://dx.doi.org/10.1377/hlthaff.23.1.213.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Liang, Jun, Min Huang, Wei Duan, Xue-Qing Yu i Shufeng Zhou. "Design of New Oxazaphosphorine Anticancer Drugs". Current Pharmaceutical Design 13, nr 9 (1.03.2007): 963–78. http://dx.doi.org/10.2174/138161207780414296.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Callingham, Brian. "Design of enzyme inhibitors as drugs". Trends in Pharmacological Sciences 10, nr 10 (październik 1989): 424–25. http://dx.doi.org/10.1016/0165-6147(89)90194-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Crowley, Patrick J., i Luigi G. Martini. "Formulation design: new drugs from old". Drug Discovery Today: Therapeutic Strategies 1, nr 4 (grudzień 2004): 537–42. http://dx.doi.org/10.1016/j.ddstr.2004.11.020.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

NAVIA, M., i P. CHATURVEDI. "Design principles for orally bioavailable drugs". Drug Discovery Today 1, nr 5 (maj 1996): 179–89. http://dx.doi.org/10.1016/1359-6446(96)10020-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Müller, Klaus, i Hans-Joachim Böhm. "Facilitating the Design of Fluorinated Drugs". Chemistry & Biology 16, nr 11 (listopad 2009): 1130–31. http://dx.doi.org/10.1016/j.chembiol.2009.11.004.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Wold, Svante. "Multidimensional Pharmacochemistry. Design of Safer Drugs." Journal of Pharmaceutical Sciences 74, nr 11 (listopad 1985): 1247. http://dx.doi.org/10.1002/jps.2600741124.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

Cereghino, James J. "Clinical trial design for antiepileptic drugs". Annals of Neurology 32, nr 3 (wrzesień 1992): 393–94. http://dx.doi.org/10.1002/ana.410320314.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

Beydoun, Ahmad. "Sequential Design Studies for Antiepileptic Drugs". Epilepsy & Behavior 3, nr 2 (kwiecień 2002): 107–8. http://dx.doi.org/10.1006/ebeh.2002.0338.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

Siddeswari T, Panneerselvam P, Vijayamma G, Nithya Kalyani K, Jeslin D i Suryasree Y. "Design and validation of the Gingkolide estimation using RP-HPLC analytical tool". International Research Journal of Pharmaceutical and Applied Sciences 11, nr 1 (26.02.2021): 1–5. http://dx.doi.org/10.26452/irjpas.v11i1.1394.

Pełny tekst źródła

Streszczenie:

Gingkolide is an antiseizure medicine used as an adjuvant of partial seizures and GAD to relieve neuropathic pain. It binds to the very high affinity alpha delta site in the CNS. Although the drug's mechanism remains unclear, in genetically engineered mice and other anticonvulsive models, findings showed that it binds to alpha receptors. A rapid rise in the number of drugs added to each class of drugs has been noted. Whether in a single or multi-drug delivery form, these medications are developed into newer formulations. These newest formulations put on the market need a new investigation to estimate the medication in the formulations. In the scientific literature, the current analytical procedures for such drugs are available, but not all approaches are stable and economical to use. Few other techniques are often time-consuming. The goal of this work was to develop an RP-HPLC analytical tool for Gingkolide estimation. The drug's RP-PLC study meets the drug's optimum integrity, suitability, regeneration. The drug's LOQ and LOD were reached with elevated sensitivity. Overall, the results show that the recommended analytical approach in the formulation should be used to evaluate the drug. For regular study of the medication in its dosage form, this approach may be recommended.

Style APA, Harvard, Vancouver, ISO itp.

30

Ning, Lin, Bifang He, Peng Zhou, Ratmir Derda i Jian Huang. "Molecular Design of Peptide-Fc Fusion Drugs". Current Drug Metabolism 20, nr 3 (22.05.2019): 203–8. http://dx.doi.org/10.2174/1389200219666180821095355.

Pełny tekst źródła

Streszczenie:

Background:Peptide-Fc fusion drugs, also known as peptibodies, are a category of biological therapeutics in which the Fc region of an antibody is genetically fused to a peptide of interest. However, to develop such kind of drugs is laborious and expensive. Rational design is urgently needed.Methods:We summarized the key steps in peptide-Fc fusion technology and stressed the main computational resources, tools, and methods that had been used in the rational design of peptide-Fc fusion drugs. We also raised open questions about the computer-aided molecular design of peptide-Fc.Results:The design of peptibody consists of four steps. First, identify peptide leads from native ligands, biopanning, and computational design or prediction. Second, select the proper Fc region from different classes or subclasses of immunoglobulin. Third, fuse the peptide leads and Fc together properly. At last, evaluate the immunogenicity of the constructs. At each step, there are quite a few useful resources and computational tools.Conclusion:Reviewing the molecular design of peptibody will certainly help make the transition from peptide leads to drugs on the market quicker and cheaper.

Style APA, Harvard, Vancouver, ISO itp.

31

Buchwald, Peter. "Computer-aided retrometabolic drug design: soft drugs". Expert Opinion on Drug Discovery 2, nr 7 (lipiec 2007): 923–33. http://dx.doi.org/10.1517/17460441.2.7.923.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

De Clercq, Erik. "Strategies in the design of antiviral drugs". Nature Reviews Drug Discovery 1, nr 1 (styczeń 2002): 13–25. http://dx.doi.org/10.1038/nrd703.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

Fricker, Simon Paul. "Metal based drugs: from serendipity to design". Dalton Transactions, nr 43 (2007): 4903. http://dx.doi.org/10.1039/b705551j.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

Pinheiro, M. P., J. R. da Rocha, J. Cheleski, H. J. Wiggers, C. A. Montanari i M. C. Nonato. "Structure-based design of anti-trypanosomal drugs". Acta Crystallographica Section A Foundations of Crystallography 67, a1 (22.08.2011): C294. http://dx.doi.org/10.1107/s0108767311092646.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Walsh, John S., i Gerald T. Miwa. "Bioactivation of Drugs: Risk and Drug Design". Annual Review of Pharmacology and Toxicology 51, nr 1 (10.02.2011): 145–67. http://dx.doi.org/10.1146/annurev-pharmtox-010510-100514.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

Deng, Xiaotie, Guojun Li, Zimao Li, Bin Ma i Lusheng Wang. "Genetic Design of Drugs Without Side-Effects". SIAM Journal on Computing 32, nr 4 (styczeń 2003): 1073–90. http://dx.doi.org/10.1137/s0097539701397825.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Jackson, Graham E., Lomkhosi Mkhonta-Gama, Alex Voyé i Mark Kelly. "Design of copper-based anti-inflammatory drugs". Journal of Inorganic Biochemistry 79, nr 1-4 (kwiecień 2000): 147–52. http://dx.doi.org/10.1016/s0162-0134(99)00171-3.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Moutevelis-Minakakis, P., M. Gianni, H. Stougiannou, P. Zoumpoulakis, A. Zoga, A. D. Vlahakos, E. Iliodromitis i T. Mavromoustakos. "Design and synthesis of novel antihypertensive drugs". Bioorganic & Medicinal Chemistry Letters 13, nr 10 (maj 2003): 1737–40. http://dx.doi.org/10.1016/s0960-894x(03)00251-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Anand, CV. "The design of drugs to macromolecular targets". Biochemical Education 22, nr 1 (styczeń 1994): 39. http://dx.doi.org/10.1016/0307-4412(94)90168-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

Larrick, James W., i Yuqiang Wang. "Pharmaceutical design II: Nucleic acid binding drugs". Gene 149, nr 1 (listopad 1994): 1–2. http://dx.doi.org/10.1016/0378-1119(94)90404-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Bradbury, Jane. "Rational design of peptide drugs: avoiding aggregation". Drug Discovery Today 10, nr 18 (wrzesień 2005): 1208–9. http://dx.doi.org/10.1016/s1359-6446(05)03603-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

BALAJI, V. N., J. SCOTT DIXON, D. H. SMITH, R. VENKATARAGHAVAN i K. C. MURDOCK. "Design of Anticancer Drugs Using Modeling Techniques". Annals of the New York Academy of Sciences 439, nr 1 Macromolecula (marzec 1985): 140–61. http://dx.doi.org/10.1111/j.1749-6632.1985.tb25794.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Cody, Vivian. "The design of drugs to macromolecular targets". Journal of Molecular Graphics 11, nr 3 (wrzesień 1993): 214. http://dx.doi.org/10.1016/0263-7855(93)80076-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Saunders, John. "The design of drugs to macromolecular targets". Trends in Pharmacological Sciences 14, nr 4 (kwiecień 1993): 135. http://dx.doi.org/10.1016/0165-6147(93)90088-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Wermuth, Camille G. "Similarity in drugs: reflections on analogue design". Drug Discovery Today 11, nr 7-8 (kwiecień 2006): 348–54. http://dx.doi.org/10.1016/j.drudis.2006.02.006.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Plescia, Jessica, i Nicolas Moitessier. "Design and discovery of boronic acid drugs". European Journal of Medicinal Chemistry 195 (czerwiec 2020): 112270. http://dx.doi.org/10.1016/j.ejmech.2020.112270.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Singh, Parvesh, i Vipan Kumar. "Special Issue “Hybrid Drugs: Design and Applications”". Pharmaceuticals 16, nr 10 (26.09.2023): 1358. http://dx.doi.org/10.3390/ph16101358.

Pełny tekst źródła

Streszczenie:

The widely held belief in the potential superiority of agents capable of modulating multiple biological targets has led to the adoption of molecular hybridization as an effective technique in the realm of drug discovery and development [...]

Style APA, Harvard, Vancouver, ISO itp.

48

Tee, Wei-Ven, i Igor N. Berezovsky. "Allosteric drugs: New principles and design approaches". Current Opinion in Structural Biology 84 (luty 2024): 102758. http://dx.doi.org/10.1016/j.sbi.2023.102758.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Gasco, Alberto, Donatella Boschi, Konstantin Chegaev, Clara Cena, Antonella Di Stilo, Roberta Fruttero, Loretta Lazzarato, Barbara Rolando i Paolo Tosco. "Multitarget drugs: Focus on the NO-donor hybrid drugs". Pure and Applied Chemistry 80, nr 8 (1.01.2008): 1693–701. http://dx.doi.org/10.1351/pac200880081693.

Pełny tekst źródła

Streszczenie:

The article addresses the design of multitarget drugs, namely, compounds capable of interacting with more than one target simultaneously. These agents could be useful tools in the therapy of complex diseases such as cardiovascular and inflammatory diseases. An interesting case of multitarget compounds are nitric oxide (NO)-donor hybrids, structures which combine the physiological properties of NO with those of a lead drug. In particular, the authors discuss the symbiotic approach used to design NO-donor nonsteroidal anti-inflammatory drugs (NO-NSAIDs) and NO-donor antioxidants. The former could be useful agents in the treatment of anti-inflammatory diseases being devoid of gastro- and cardiotoxicity, the latter could be a valid approach to the treatment of many cardiovascular diseases.

Style APA, Harvard, Vancouver, ISO itp.

50

Meegan, Mary J., i Niamh M. O’Boyle. "Special Issue “Anticancer Drugs”". Pharmaceuticals 12, nr 3 (16.09.2019): 134. http://dx.doi.org/10.3390/ph12030134.

Pełny tekst źródła

Streszczenie:

The focus of this Special Issue of Pharmaceuticals is on the design, synthesis, and molecular mechanism of action of novel antitumor, drugs with a special emphasis on the relationship between the chemical structure and the biological activity of the molecules. This Special Issue also provides an understanding of the biologic and genotypic context in which targets are selected for oncology drug discovery, thus providing a rationalization for the biological activity of these drugs and guiding the design of more effective agents. In this Special Issue of Pharmaceuticals dedicated to anticancer drugs, we present a selection of preclinical research papers including both traditional chemotherapeutic agents and newer more targeted therapies and biological agents. We have included articles that report the design of small molecules with promising anticancer activity as tubulin inhibitors, vascular targeting agents, and topoisomerase targeting agents, alongside a comprehensive review of clinically successful antibody-drug conjugates used in cancer treatment.

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!